Japan Appetite (Eating) Disorder Market Analysis

Japan Appetite (Eating) Disorder Market Executive Summary

Japan Appetite (Eating) Disorder Market is valued at around $32.9 Bn in 2022 and is projected to reach $51.3 Bn by 2030, exhibiting a CAGR of 5.7% during the forecast period 2023-2030.

Appetite Disorder Market refers to the market for treatment of serious mental illness characterized by abnormal eating patterns and thoughts about food and weight. Most common eating disorders include bulimia nervosa, anorexia nervosa, and binge eating disorder. The market includes therapy, medication, hospitalization, and sometimes specialized treatment depending upon the condition of patient.

Prevalence of appetite disorders is increasing, there were around 9% of people suffering from eating disorders in 2022. Age of these patients were between 15 to 49 years. Increasing prevalence has contributed to the growth of global market for Appetite disorder in recent years. Advancement in treatments has improved patient satisfaction and outcome.

There are many firms in Appetite disorder market but Bausch & Lomb Incorporated, Somerset Therapeutics, LLC, Equip, Teva Pharmaceuticals Industries Ltd, Mylan N.V., Pfizer Inc., Amneal Pharmaceutical LLC, Sun Pharmaceutical Industries Ltd, Moriah Behavioral Health, and Eli Lilly and Company are major firms.

Appetite disorders are diagnosed and treated using multidisciplinary approach which involves medical, nutritional, and psychological intervention. It involves doctors, psychiatrists, psychologists, and dieticians who provides comprehensive care to the patient with appetite disorder. Different type of therapies like cognitive behavior therapy, dialectical behavior therapy and interpersonal therapy are included in treatment with medicines. These therapies and medicines are being improved with time.  

Increasing awareness and prevalence of appetite disorders, advancement in treatment approaches and government initiatives are projected to grow the market in coming year. There are still many difficulties like lack of evidence-based treatment, high cost of treatment and social stigma among people.

Market Dynamics

Drivers of Japan Appetite (Eating) Disorder Market:

Increasing Prevalence of Appetite Disorders: Increasing prevalence of appetite disorders is driven by societal pressure, increasing concerns about body image, and cultural influences. With respect to genetics, identical twins are more likely to develop eating disorders compared to fraternal twins or others. According to WHO around 620 million people had eating disorder in 2022. Rising prevalence indicates the larger potential for Appetite disorder market.

Technological Advancements: Telehealth solutions and digital technologies have gained importance in healthcare industry. It has improved treatment delivery, remote counselling and monitoring of patients, and self-management tools and patient engagement and satisfaction. It has expanded market for Appetite disorder and overall care of patients.

Advancements in Treatment Approaches: New therapeutic interventions, medications, and technologies are aimed to improve patient outcome and experiences. Research and development in appetite disorders have ben increased in recent years for improvement in treatment and more patient-centric approach. Innovations are providing more effective and efficient treatment.

Increasing Mental Health Awareness: People are giving more attention and support to mental health and understanding its importance in accordance with appetite disorders. Individuals seeking help are increasing because of mental health awareness and it has contributed to market growth.

Government Initiatives: Governments throughout the world are supporting mental health awareness, education, and providing funding for research which can positively impact the Appetite disorder market. Governments are making policies which support early intervention, accessibility to treatment, and insurance coverage for mental health diseases which can drive the market for Appetite disorder market. 

Restraints of Japan Appetite (Eating) Disorder Market:

Social Stigma and Lack of Awareness: People are getting more aware about mental disorders, but still there is stigma for seeking help or treatment for eating or appetite disorder. Fear of judgement or misunderstanding from family members, friends and society is a major factor for this stigma. Sometimes healthcare professionals are also unaware of about these disorders which leads to underdiagnosis and undertreatment.

High Cost of Treatment: Treatment for appetite disorders can be expensive as it involves cost of therapy, medication, hospitalization, and sometimes specialized treatment depending upon the stage of disorder. In this comprehensive treatment and multiple specialists are required which increases cost and financial burden on patients and their family. Higher financial burden of treatment limits patients with lower income and affects growth of market.

Limited Research and Evidence: there is continuous research going on regarding these disorders but still it is not enough and requires much more learning. Evidence-based guidelines for treatment of appetite disorders are very limited which can hinder the growth of market for appetite disorder.

Comorbidities and Complexities: Depression, anxiety and substance abuse are often associated with appetite disorders. Treating patients with multiple conditions can be challenging and requires amalgamation of multiple therapies with different healthcare providers.

Resistance and Relapse of Treatment: Relapse and resistance rate are higher for treatment of appetite disorders due to complex conditions. It is challenging to achieve long term recovery as patients require ongoing treatment for long period even after initial improvement. These disorders are recurrent in nature and requires monitoring and guidance for longer period.